GoodRx, a resource for healthcare savings and information, is working with Sanofi, a company that specializes in diabetes care, to offer people living with diabetes access to Lantus (insulin glargine ...

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (NASDAQ: GDRX), a leading resource for healthcare savings and information, today announced it is working with Sanofi (NASDAQ: SNY), a global leader in ...

GoodRx announced Thursday morning that it is working with Sanofi on a program to offer one of its leading insulin products to consumers for $35 per month. By visiting ...

Eli Lilly announced it will automatically cap out-of-pocket (OOP) costs at $35 at participating retail pharmacies for Americans with commercial insurance using some of its insulin products. Eli Lilly ...

(RTTNews) - Viatris Inc. (VTRS) and Biocon Biologics Ltd. announced the U.S. launch of interchangeable biosimilars SEMGLEE injection, a branded product, and Insulin Glargine injection, an unbranded ...

Today, the U.S. Food and Drug Administration approved the first interchangeable biosimilar insulin product, indicated to improve glycemic control in adults and pediatric patients with Type 1 diabetes ...

Oct 19 (Reuters) - GoodRx (GDRX.O), opens new tab said on Thursday it has collaborated with Sanofi (SASY.PA), opens new tab to offer the drugmaker's most-prescribed insulin injection Lantus for only ...